既往化疗对尿路上皮癌二线帕博利珠单抗治疗反应的影响:KEYNOTE-045 3期试验的探索性分析
本文为 KEYNOTE-045 3期试验的事后分析,评估既往铂类化疗最佳反应对二线帕博利珠单抗疗效的影响。晚期尿路上皮癌患者按1:1随机接受帕博利珠单抗 200 mg 每3周(≤2年)或研究者选择的化疗。各亚组中帕博利珠单抗的中位总生存期、客观缓解率和中位缓解持续时间在数值上均优于化疗,但缺乏正式假设检验。
要点
- 各亚组中帕博利珠单抗的中位总生存期、客观缓解率和中位缓解持续时间在数值上均优于化疗。
- 对既往铂类化疗最佳反应为疾病进展的患者总生存结局最差。
- 与化疗相比,二线帕博利珠单抗的延长总生存期和持久缓解不依赖于既往铂类化疗的反应或类型。
核心结论
- 与化疗相比,二线帕博利珠单抗的延长总生存期和持久缓解不依赖于既往铂类化疗的反应或类型。
- 这些发现进一步支持帕博利珠单抗作为晚期尿路上皮癌的二线治疗。
研究设计与样本
- KEYNOTE-045 3期试验的事后分析。
- 一线铂类化疗后进展或复发的晚期尿路上皮癌患者按1:1随机接受帕博利珠单抗 200 mg 每3周(≤2年)或研究者选择的化疗(紫杉醇 175 mg/m2、多西他赛 75 mg/m2 或长春氟宁 320 mg/m2,均每3周)。
- 终点包括自末次治疗开始至死亡的总生存期、客观缓解率以及按实体瘤疗效评价标准1.1版自首次缓解日起计的缓解持续时间。
主要发现
- 各亚组中帕博利珠单抗的中位总生存期、客观缓解率和中位缓解持续时间在数值上均大于化疗。
- 对既往铂类化疗最佳反应为疾病进展的患者总生存结局最差。
- 在各组中均观察到帕博利珠单抗的客观缓解,依据为既往一线铂类化疗的反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏正式假设检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Until recently, the standard first-line treatment for advanced urothelial carcinoma (UC) was platinum-based combination chemotherapy followed by avelumab maintenance therapy for patients without progressive disease (PD). For patients with advanced UC who experience PD or recurrence, standard-of-care treatment is pembrolizumab monotherapy based on the phase 3 KEYNOTE-045 study. This post hoc analysis of the KEYNOTE-045 study evaluated the efficacy of pembrolizumab compared with chemotherapy by the best response to prior platinum-based chemotherapy. METHODS: Patients with advanced UC that progressed or recurred after first-line platinum-based chemotherapy were randomly assigned 1:1 to receive either pembrolizumab 200 mg every 3 wk (Q3W) for ≤2 yr or investigator's choice of chemotherapy (paclitaxel [175 mg/m2], docetaxel [75 mg/m2], or vinflunine [320 mg/m2], each Q3W). Endpoints included overall survival (OS) from the initiation of the last treatment prior to death, objective response rate (ORR), and duration of response (DOR) as per Response Evaluation Criteria in Solid Tumors version 1.1 from the date of the first response. KEY FINDINGS AND LIMITATIONS: An objective response to pembrolizumab was observed in all groups in terms of a prior response to first-line platinum-based chemotherapy. Median OS, ORR, and median DOR were numerically greater with pembrolizumab than with chemotherapy across subgroups. Patients with PD as the best response to prior platinum-based chemotherapy had the poorest OS outcomes. Limitations include a lack of formal hypothesis testing. CONCLUSIONS AND CLINICAL IMPLICATIONS: When compared with chemotherapy, prolonged OS and durable responses to second-line pembrolizumab were observed independently of the response to or type of prior platinum-based chemotherapy. These findings further support pembrolizumab as second-line treatment for advanced UC.
引用
- de Wit R, Vaughn DJ, Fradet Y, et al. Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial. Eur Urol. 2024. PMID: 39174409. doi:10.1016/j.eururo.2024.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。